Verrica Pharmaceuticals Inc.
VRCA Healthcare Biotechnology
Verrica Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $35.6 million, up 370.2% from fiscal 2024. In the quarter to June 2026, revenue fell 53.9%, EPS fell 3,200.0%, free cash flow grew 7.63% and total debt fell 97.9%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow VRCA
Verrica Pharmaceuticals Inc. (VRCA) Piotroski F-score
Verrica Pharmaceuticals Inc.'s Piotroski F-score for fiscal 2025 is 6 out of 9: 6 of nine tests of profitability, leverage and efficiency passed, up from 3 in fiscal 2024.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2025 | 6 | 3.00 |
| FY2024 | 3 | 2.00 |
| FY2023 | 1 | — |
How fiscal 2025’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | (35.33%) | (112.84%) | Fail | 0 |
| Positive operating cash flow | (17.63m) | (60.93m) | Fail | 0 |
| Rising return on assets | (35.33%) | (112.84%) | Pass | 1 |
| Cash flow above net income | 259.00k | 15.65m | Pass | 1 |
| Falling long-term leverage | 0.01 | 0.47 | Pass | 1 |
| Rising current ratio | 2.59 | 1.76 | Pass | 1 |
| No new shares issued | 10,652,400 | 5,180,800 | Fail | 0 |
| Rising gross margin | 90.33% | 63.79% | Pass | 1 |
| Rising asset turnover | 0.70 | 0.11 | Pass | 1 |
| Piotroski F-score | Mixed | 6 | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| VRCA Verrica Pharmaceuticals Inc. | 6 |
| HYFT MindWalk Holdings Corp. compare | 6 |
| FBIO Fortress Biotech, Inc. compare | 5 |
| SPRO Spero Therapeutics, Inc. compare | 5 |
| CSBR Champions Oncology, Inc. compare | 3 |
| XBIT XBiotech Inc. compare | 3 |
| NMAD Nomad Power Solutions, Inc. compare | — |
| CING Cingulate Inc. compare | — |
| OSTX OS Therapies Incorporated compare | — |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover